Targeting tumor neovasculature in non-small-cell lung cancer

Critical Reviews in Oncology/Hematology

Volumn 86, Issue 2, 2013, Pages 130-142

  Pallis, Athanasios G ^a   Syrigos, Konstantinos N ^b  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b SOTIRIA GENERAL HOSPITAL   (Greece)

Author keywords

Angiogenesis; Bevacizumab; NSCLC; VEGF; VEGFR

Indexed keywords

AFLIBERCEPT; AXITINIB; BEVACIZUMAB; BIOLOGICAL MARKER; CARBOPLATIN; CEDIRANIB; CISPLATIN; DOCETAXEL; ERLOTINIB; GEMCITABINE; MOTESANIB; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; NINTEDANIB; PACLITAXEL; PAZOPANIB; PEMETREXED; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; VADIMEZAN; VANDETANIB; VASCULAR TARGETING AGENT; VASCULOTROPIN;

ANOREXIA; BLEEDING; BLOOD PRESSURE MEASUREMENT; BRAIN ISCHEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CONFUSION; DIARRHEA; DISSEMINATED INTRAVASCULAR CLOTTING; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; DYSPNEA; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HEART EJECTION FRACTION; HEMOPTYSIS; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPONATREMIA; LIVER TOXICITY; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MOLECULAR PATHOLOGY; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PNEUMOTHORAX; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PROTEINURIA; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; THROMBOSIS; TRACHEOESOPHAGEAL FISTULA; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG; LUNG NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84875119425     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2012.10.003     Document Type: Review

References (96)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA: A Cancer Journal for Clinicians 2011, 61:69-90.
2. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. Journal of Clinical Oncology 2008, 26:4617-4625.
3. Carney D.N. Lung cancer - time to move on from chemotherapy. The New England Journal of Medicine 2002, 346:126-128.
4. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nature Medicine 2000, 6:389-395.
5. Folkman J. Angiogenesis: an organizing principle for drug discovery?. Nature Reviews Drug Discovery 2007, 6:273-286.
6. Folkman J. Role of angiogenesis in tumor growth and metastasis. Seminars in Oncology 2002, 29:15-18.
7. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nature Medicine 2003, 9:669-676.
8. Leung D.W., Cachianes G., Kuang W.J., Goeddel D.V., Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246:1306-1309.
9. Ferrara N., Davis-Smyth T. The biology of vascular endothelial growth factor. Endocrine Reviews 1997, 18:4-25.
10. Kerbel R.S. Tumor angiogenesis. The New England Journal of Medicine 2008, 358:2039-2049.
11. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocrine Reviews 2004, 25:581-611.
12. Fontanini G., Vignati S., Boldrini L., et al. Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clinical Cancer Research 1997, 3:861-865.
13. Yuan A., Yu C.J., Kuo S.H., et al. Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer. Journal of Clinical Oncology 2001, 19:432-441.
14. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.
15. Pallis A.G., Serfass L., Dziadziusko R., et al. Targeted therapies in the treatment of advanced/metastatic NSCLC. European Journal of Cancer 2009, 45:2473-2487.
16. Sandler A., Gray R., Perry M.C., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. The New England Journal of Medicine 2006, 355:2542-2550.
17. Reck M., von Pawel J., Zatloukal P., et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. Journal of Clinical Oncology 2009, 27:1227-1234.
18. Reck M., von Pawel J., Zatloukal P., et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Annals of Oncology 2010, 21:1804-1809.
19. Ramalingam S.S., Dahlberg S.E., Langer C.J., et al. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. Journal of Clinical Oncology 2008, 26:60-65.
20. Leighl N.B., Zatloukal P., Mezger J., et al. Efficacy and safety of bevacizumab-based therapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer in the phase III BO17704 study (AVAiL). Journal of Thoracic Oncology 2010, 5:1970-1976.
21. Crino L., Dansin E., Garrido P., et al. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncology 2010, 11:733-740.
22. Jager E., Wu Y., Mezger J., et al. Safety of first-line bevacizumab (bv) plus chemotherapy in elderly patients (pts) with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): MO19390 (SAIL) study group. Annals of Oncology 2008, 19. abstr 240P.
23. Brahmer J.R., Dahlberg S.E., Gray R.J., et al. Sex differences in outcome with bevacizumab therapy: analysis of patients with advanced-stage non-small cell lung cancer treated with or without bevacizumab in combination with paclitaxel and carboplatin in the Eastern Cooperative Oncology Group Trial 4599. Journal of Thoracic Oncology 2011, 6:103-108.
24. Wozniak A., Garst J., Jahanzeb M., et al. Clinical outcomes (CO) for special populations of patients (pts) with advanced non-small cell lung cancer (NSCLC): results from ARIES, a bevacizumab (BV) observational cohort study (OCS). Journal of Clinical Oncology 2010, 28. abstr 7618.
25. Socinski M.A., Langer C.J., Huang J.E., et al. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. Journal of Clinical Oncology 2009, 27:5255-5261.
26. Hainsworth J.D., Fang L., Huang J.E., et al. BRIDGE: an open-label phase II trial evaluating the safety of bevacizumab+carboplatin/paclitaxel as first-line treatment for patients with advanced, previously untreated, squamous non-small cell lung cancer. Journal of Thoracic Oncology 2011, 6:109-114.
27. Leighl N.B., Raez L.E., Besse B., et al. A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung. Journal of Thoracic Oncology 2010, 5:1054-1059.
28. Wilhelm S.M., Carter C., Tang L., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Research 2004, 64:7099-7109.
29. Dy G.K., Hillman S.L., Rowland K.M., et al. A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer: North Central Cancer Treatment Group Study N0326. Cancer 2010, 116:5686-5693.
30. Blumenschein G.R., Gatzemeier U., Fossella F., et al. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. Journal of Clinical Oncology 2009, 27:4274-4280.
31. Schiller H.J., Lee J.W., Hanna N.H., Traynor A.M., Carbone D.P. A randomized discontinuation phase II study of sorafenib versus placebo in patients with non-small cell lung cancer who have failed at least two prior chemotherapy regimens: E2501. Journal of Clinical Oncology 2008, 26.
32. Okamoto I., Miyazaki M., Morinaga R., et al. Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Investigational New Drugs 2010, 28:844-853.
33. Flaherty K.T., Schiller J., Schuchter L.M., et al. A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clinical Cancer Research 2008, 14:4836-4842.
34. Scagliotti G., Novello S., von Pawel J., et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. Journal of Clinical Oncology 2010, 28:1835-1842.
35. Paz-Ares L.G., Biesma B., Heigener D., et al. Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. Journal of Clinical Oncology 2012, 30:3084-3092.
36. Kim E.S., Herbst R.S., Wistuba I.I., et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discovery 2011, 1:44-53.
37. Smit E.F., Dingemans A.M., Thunnissen F.B., Hochstenbach M.M., van Suylen R.J., Postmus P.E. Sorafenib in patients with advanced non-small cell lung cancer that harbor K-ras mutations: a brief report. Journal of Thoracic Oncology 2010, 5:719-720.
38. Socinski M.A., Novello S., Brahmer J.R., et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. Journal of Clinical Oncology 2008, 26:650-656.
39. Novello S., Scagliotti G.V., Rosell R., et al. Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer. British Journal of Cancer 2009, 101:1543-1548.
40. Socinski M., Scappaticci F.A., Samant M., Kolb M.M., Kozloff M. Safety and efficacy of combining sunitinib with bevacizumab+paclitaxel/carboplatin in non-small cell lung cancer. Journal of Thoracic Oncology 2010, 5:354-360.
41. Sonpavde G., Hutson T.E. Pazopanib: a novel multitargeted tyrosine kinase inhibitor. Current Oncology Reports 2007, 9:115-119.
42. Schutz F.A., Choueiri T.K., Sternberg C.N., Pazopanib: Clinical development of a potent anti-angiogenic drug. Critical Reviews in Oncology/Hematology 2011, 77:163-171.
43. Altorki N., Lane M.E., Bauer T., et al. Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer. Journal of Clinical Oncology 2010, 28:3131-3137.
44. Wedge S.R., Kendrew J., Hennequin L.F., et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Research 2005, 65:4389-4400.
45. Laurie S.A., Gauthier I., Arnold A., et al. Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group. Journal of Clinical Oncology 2008, 26:1871-1878.
46. Goss G.D., Arnold A., Shepherd F.A., et al. Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study. Journal of Clinical Oncology 2010, 28:49-55.
47. Gadgeel S.M., Wozniak A., Edelman M., et al. Cediranib, a VEGF receptor 1, 2, and 3 inhibitor, and pemetrexed in patients (pts) with recurrent non-small cell lung cancer (NSCLC). Journal of Clinical Oncology 2009, 27. abstr e19007.
48. Hilberg F., Roth G.J., Krssak M., et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Research 2008, 68:4774-4782.
49. Reck M., Kaiser R., Eschbach C., et al. A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer. Annals of Oncology 2011, 22:1374-1381.
50. Ellis P.M., Kaiser R., Zhao Y., Stopfer P., Gyorffy S., Hanna N. Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patients. Clinical Cancer Research 2010, 16:2881-2889.
51. Hu-Lowe D.D., Zou H.Y., Grazzini M.L., et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clinical Cancer Research 2008, 14:7272-7283.
52. Schiller J.H., Larson T., Ou S.H., et al. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study. Journal of Clinical Oncology 2009, 27:3836-3841.
53. Martin L., Kozloff M., Krzakowski M., et al. Axitinib (AG-013736; AG) combined with chemotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) and other solid tumors. Journal of Clinical Oncology 2009, 27. abstr 3559.
54. Polverino A., Coxon A., Starnes C., et al. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Research 2006, 66:8715-8721.
55. Scagliotti G., Vynnychenko I., Ichinose Y., et al. An international, randomized, placebo-controlled, double-blind phase III study (MONET1) of motesanib plus carboplatin/paclitaxel (C/P) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC). Journal of Clinical Oncology 2012, 30:2829-2836.
56. Thorpe P.E. Vascular targeting agents as cancer F therapeutics. Clinical Cancer Research 2004, 10:415-427.
57. Head M., Jameson M.B. The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities. Expert Opinion on Investigational Drugs 2010, 19:295-304.
58. McKeage M.J., Von Pawel J., Reck M., et al. Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. British Journal of Cancer 2008, 99:2006-2012.
59. Lara P.N., Douillard J.Y., Nakagawa K., et al. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. Journal of Clinical Oncology 2011, 29:2965-2971.
60. Novartis discontinues ASA404 clinical trial program and shifts focus to other cancer compounds in early and late stage development 2010, Novartis, Basel, Switzerland. http://www.novartis.com/newsroom/media-releases/en/2010/1461276.shtml.
61. Rudin C.M., Mauer A., Smakal M., et al. Phase I/II study of pemetrexed with or without ABT-751 in advanced or metastatic non-small-cell lung cancer. Journal of Clinical Oncology 2011, 29:1075-1082.
62. Herbst R.S., O'Neill V.J., Fehrenbacher L., et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. Journal of Clinical Oncology 2007, 25:4743-4750.
63. Herbst R.S., Johnson D.H., Mininberg E., et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. Journal of Clinical Oncology 2005, 23:2544-2555.
64. Zappa F., Droege C., Betticher D., et al. Bevacizumab (B) and erlotinib (E) as first-line therapy in metastatic nonsquamous non-small cell lung cancer (NSCLC) followed by platinum-based chemotherapy (CT) at disease progression (PD): a multicenter phase II trial, SAKK 19/05. Journal of Clinical Oncology 2011, 79. abstr 7651.
65. Herbst R.S., Ansari R., Bustin F., et al. Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet 2011, 377:1846-1854.
66. Kabbinavar F., Miller V.A., Johnson B.E., O'Connor P., Soh C. Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). Journal of Clinical Oncology 2010, 28. for the Ai, abstr 7526.
67. Heymach J.V., Johnson B.E., Prager D., et al. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. Journal of Clinical Oncology 2007, 25:4270-4277.
68. Natale R.B., Bodkin D., Govindan R., et al. Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study. Journal of Clinical Oncology 2009, 27:2523-2529.
69. Commander H., Whiteside G., Perry C. Vandetanib: first global approval. Drugs 2011, 71:1355-1365.
70. Dahlberg S.E., Sandler A.B., Brahmer J.R., Schiller J.H., Johnson D.H. Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. Journal of Clinical Oncology 2010, 28:949-954.
71. Rini B.I., Schiller H.J., Fruehauf J.P., et al. Association of diastolic blood pressure (dBP)>90mmHg with overall survival (OS) in patients treated with axitinib (AG-013736). Journal of Clinical Oncology 2008, 26. abstr 3543.
72. Hanrahan E.O., Ryan A.J., Mann H., et al. Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. Clinical Cancer Research 2009, 15:3600-3609.
73. Bonnesen B., Pappot H., Holmstav J., Skov B.G. Vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 expression in non-small cell lung cancer patients: relation to prognosis. Lung Cancer 2009, 66:314-318.
74. Dowlati A., Gray R., Sandler A.B., Schiller J.H., Johnson D.H. Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab - an Eastern Cooperative Oncology Group Study. Clinical Cancer Research 2008, 14:1407-1412.
75. Heist R.S., Zhai R., Liu G., et al. VEGF polymorphisms and survival in early-stage non-small-cell lung cancer. Journal of Clinical Oncology 2008, 26:856-862.
76. Jain R.K., Duda D.G., Willett C.G., et al. Biomarkers of response and resistance to antiangiogenic therapy. Nature Reviews Clinical Oncology 2009, 6:327-338.
77. Shojaei F., Wu X., Malik A.K., et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nature Biotechnology 2007, 25:911-920.
78. Relf M., LeJeune S., Scott P.A., et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Research 1997, 57:963-969.
79. Leenders W.P., Kusters B., Verrijp K., et al. Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option. Clinical Cancer Research 2004, 10:6222-6230.
80. Karashima T., Inoue K., Fukata S., et al. Blockade of the vascular endothelial growth factor-receptor 2 pathway inhibits the growth of human renal cell carcinoma, RBM1-IT4, in the kidney but not in the bone of nude mice. International Journal of Clinical Oncology 2007, 30:937-945.
81. Casanovas O., Hicklin D.J., Bergers G., Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005, 8:299-309.
82. Fischer C., Jonckx B., Mazzone M., et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007, 131:463-475.
83. Batchelor T.T., Sorensen A.G., di Tomaso E., et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007, 11:83-95.
84. Motzer R.J., Michaelson M.D., Redman B.G., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology 2006, 24:16-24.
85. Willett C.G., Boucher Y., Duda D.G., et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. Journal of Clinical Oncology 2005, 23:8136-8139.
86. Yu J.L., Rak J.W., Coomber B.L., Hicklin D.J., Kerbel R.S. Effect of p53 status on tumor response to antiangiogenic therapy. Science 2002, 295:1526-1528.
87. Glade Bender J., Cooney E.M., Kandel J.J., Yamashiro D.J. Vascular remodeling and clinical resistance to antiangiogenic cancer therapy. Drug Resistance Updates 2004, 7:289-300.
88. Shepherd F.A. Molecular selection trumps clinical selection. Journal of Clinical Oncology 2011, 29:2843-2844.
89. Bayer Healthcare Pharmaceuticals Inc., Onyx Pharmaceuticals Inc. Phase 3 trial of Nexavar in first-line advanced non-small cell lung cancer does not meet primary endpoint of overall survival June 14, 2010, Available from:, [accessed 29.09.11]. http://wwwonyx-pharmcom/viewcfm/685/Phase-3-Trial-of-Nexavar-in-First-Line-Advanced-Non-Small-Cell-Lung-Cancer-Does-Not-Meet-Primary-Endpoint-of-Overall-Survival.
90. Reck M. BIBF 1120 for the treatment of non-small cell lung cancer. Expert Opinion on Investigational Drugs 2010, 19:789-794.
91. Gauler T.C., Besse B., Mauguen A., et al. Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC). Annals of Oncology 2011, 23:678-687.
92. Miller V.A., O'Connor P., Soh C., Kabbinavar F. A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). Journal of Clinical Oncology 2009, 27:LBA8002. for the Ai.
93. Herbst R.S., Sun Y., Eberhardt W.E., et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncology 2010, 11:619-626.
94. de Boer R.H., Arrieta O., Yang C.H., et al. Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. Journal of Clinical Oncology 2011, 29:1067-1074.
95. Natale R.B., Thongprasert S., Greco F.A., et al. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. Journal of Clinical Oncology 2011, 29:1059-1066.
96. Lee J., Hirsh V., Park K., et al. Vandetanib versus placebo in patients with advanced non-small cell lung cancer (NSCLC) after prior therapy with an EGFR tyrosine kinase inhibitor (TKI): a randomized, double-blind phase III trial (ZEPHYR). Journal of Clinical Oncology 2010, 28. abstr 7525.